A detailed history of Natixis Advisors, L.P. transactions in Corcept Therapeutics Inc stock. As of the latest transaction made, Natixis Advisors, L.P. holds 32,123 shares of CORT stock, worth $2.34 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
32,123
Previous 28,144 14.14%
Holding current value
$2.34 Million
Previous $1.3 Million 24.25%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 10, 2025

BUY
$44.66 - $60.85 $177,702 - $242,122
3,979 Added 14.14%
32,123 $1.62 Million
Q3 2024

Nov 06, 2024

BUY
$29.51 - $46.26 $220,852 - $346,209
7,484 Added 36.22%
28,144 $1.3 Million
Q2 2024

Aug 01, 2024

BUY
$22.21 - $34.48 $63,387 - $98,405
2,854 Added 16.03%
20,660 $671,000
Q1 2024

Apr 25, 2024

SELL
$21.1 - $27.46 $86,531 - $112,613
-4,101 Reduced 18.72%
17,806 $449,000
Q4 2023

Feb 06, 2024

SELL
$24.82 - $32.88 $46,810 - $62,011
-1,886 Reduced 7.93%
21,907 $711,000
Q3 2023

Nov 13, 2023

BUY
$21.97 - $33.8 $108,114 - $166,329
4,921 Added 26.08%
23,793 $648,000
Q2 2023

Aug 15, 2023

SELL
$21.44 - $25.15 $34,625 - $40,617
-1,615 Reduced 7.88%
18,872 $420,000
Q1 2023

May 11, 2023

BUY
$19.2 - $24.47 $109,632 - $139,723
5,710 Added 38.64%
20,487 $444,000
Q4 2022

Jan 27, 2023

SELL
$19.95 - $29.96 $82,253 - $123,525
-4,123 Reduced 21.81%
14,777 $300,000
Q3 2022

Nov 14, 2022

BUY
$24.7 - $29.12 $59,280 - $69,888
2,400 Added 14.55%
18,900 $485,000
Q2 2022

Aug 12, 2022

SELL
$17.33 - $25.3 $36,063 - $52,649
-2,081 Reduced 11.2%
16,500 $392,000
Q1 2022

May 12, 2022

BUY
$16.53 - $25.21 $111,180 - $169,562
6,726 Added 56.74%
18,581 $418,000
Q4 2021

Feb 08, 2022

BUY
$17.1 - $23.34 $202,720 - $276,695
11,855 New
11,855 $235,000

Others Institutions Holding CORT

About CORCEPT THERAPEUTICS INC


  • Ticker CORT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 107,105,000
  • Market Cap $7.79B
  • Description
  • Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients ...
More about CORT
Track This Portfolio

Track Natixis Advisors, L.P. Portfolio

Follow Natixis Advisors, L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Natixis Advisors, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Natixis Advisors, L.P. with notifications on news.